The randomized, pracedo-controlled, double brind crinical trial for the choroidal circulation of 12mg astaxanthin ingestion.

The randomized, pracedo-controlled, double brind crinical trial for the choroidal circulation of 12mg astaxanthin ingestion. - The crinical trial for the choroidal circulation of 12mg astaxanthin ingestion.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004754

Enrollment

Registered

2010-12-20

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choroidal circulation disorder

Interventions

The 12mg astaxanthin capsules ingestion for 4 weeks. The placebo capsules ingestion for 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healty subjects

Exclusion criteria

Exclusion criteria: The subjects who were pregnant or any systemic or ocular abnormalities were found.

Design outcomes

Primary

Measure	Time frame
The choroidal circulation, the mean blur rate measured by laser speckle flowgraphy, at 4 weeks after the initiation of ingestion.	—

Secondary

Measure	Time frame
The choroidal circulation, the mean blur rate measured by laser speckle flowgraphy, at 2 and 4 weeks after the initiation of ingestion and the conplications.	—

Countries

Japan

Contacts

Public ContactMichiyuki Saito

Hokkaido University Graduate School of Medicine Department of Ocular inflammation and Immunology

s.mitiyuki@gmail.com+81-11-706-5944

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026